The DMD Knockout HAP1 Polyclonal Cells constitute a CRISPR/Cas9-mediated loss-of-function model targeting the DMD gene in a polyclonal knockout cell population. Derived from the HAP1 cell line, this product provides a heterogeneous pool of edited cells for investigating dystrophin biology and disease mechanisms. Unlike clonal isolates, the polyclonal format preserves population-level diversity, enabling robust assessment of gene disruption effects in a near-haploid genomic background. This knockout cell population serves as a versatile tool for functional genomics, drug testing, and mechanistic studies centered on the dystrophin protein. The CRISPR/Cas9 approach ensures targeted gene disruption without introducing specific selection markers, maintaining a physiologically relevant genomic context for downstream analyses.
The HAP1 cell line is a nearly haploid human cell line originally derived from a male patient with chronic myeloid leukemia (CML). Its near-haploid karyotype simplifies gene editing by requiring disruption of only a single allele for complete loss-of-function, enhancing knockout efficiency. HAP1 cells exhibit adherent growth and retain key signaling pathways relevant to cancer biology and beyond, making them a preferred model for high-throughput functional genomics screens. Despite their non-muscle origin, HAP1 cells express many components of the dystrophin-associated glycoprotein complex, permitting the study of dystrophin??s molecular interactions and signaling functions in a tractable cell system. The stable genetic background and ease of culture further support reproducibility in downstream assays.
The DMD gene encodes dystrophin, a large cytoskeletal protein that mechanically links the intracellular actin cytoskeleton to the extracellular matrix via the dystrophin-glycoprotein complex (DGC). Dystrophin??s primary role is to stabilize the sarcolemma during muscle contraction, transmitting force and maintaining membrane integrity. Its function is regulated upstream by muscle-specific transcription factors such as MyoD and MEF2, along with epigenetic modifiers that control muscle gene expression. Downstream, dystrophin facilitates sarcolemmal stabilization, calcium homeostasis, mechanotransduction, and nNOS signaling. The DGC includes multiple interacting partners: dystrophin binds actin and the transmembrane ??-dystroglycan, which associates with ??-dystroglycan linking to laminin-??2 in the matrix. Additional components??sarcoglycans (??, ??, ??, ??), syntrophins, dystrobrevins, and sarcospan??form a scaffold that anchors signaling molecules like nNOS to the membrane. Disruption of dystrophin leads to loss of DGC integrity, causing increased membrane permeability, calcium influx, and activation of degenerative pathways, as seen in Duchenne muscular dystrophy.
Although HAP1 cells are not of muscle lineage, the DMD knockout in this background offers significant experimental advantages. The near-haploid genome ensures that CRISPR/Cas9-mediated disruption of the single DMD allele results in a homogeneous loss-of-function at the protein level, eliminating the need for generating homozygous knockouts in diploid cells. This model is particularly suited for studying conserved aspects of dystrophin biology, such as its role in mechanotransduction, calcium signaling, and protein complex formation, which are not strictly muscle-specific. Researchers can interrogate how loss of dystrophin affects cell adhesion, cytoskeletal organization, and downstream signaling pathways in a simplified cellular environment. The polyclonal nature provides a broader representation of editing outcomes, mimicking the genetic heterogeneity observed in patient populations, which is valuable for drug screening and therapeutic testing.
The DMD Knockout HAP1 Polyclonal Cells enable a wide array of research applications. They serve as a platform for modeling aspects of Duchenne and Becker muscular dystrophies, evaluating small-molecule or genetic therapies aimed at dystrophin restoration, and validating gene therapy vectors. Typical assays include western blotting and immunofluorescence to assess dystrophin expression, RT-qPCR and RNA-seq for transcriptomic profiling, calcium influx measurements to evaluate membrane integrity, and membrane damage assays such as Evans blue dye uptake. Additionally, these cells facilitate drug screening for read-through compounds, exon-skipping approaches, and CRISPR-based editing strategies targeting DMD mutations. For further information on product availability and customization, please contact Ascent Research.
